Physician profile
Timothy Vierling
NPI 1336250380
$1,703.73
in general payments reported to CMS, 2019-2025
30 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.86 · 2020: $106 · 2021: $199 · 2022: $381 · 2023: $543 · 2024: $221 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.73 | 2019-2024 | Ubrelvy, Orilissa, Lo Loestrin Fe |
| Amgen INC. | $137.20 | 2021-2024 | Evenity, Prolia |
| Aspira Women'S Health INC | $137.01 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $120.45 | 2023-2025 | Myfembree |
| Organon LLC | $116.04 | 2022-2025 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $102.67 | 2020-2024 | Paragard T 380a |
| Shield Therapeutics INC | $100.48 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $74.12 | 2023-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Exeltis, USA INC. | $73.46 | 2022-2024 | Slynd |
| Therapeuticsmd, INC. | $72.48 | 2020-2021 | |
| Astellas Pharma US INC | $63.28 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $56.00 | 2023-2024 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $39.81 | 2023 | Bd Max System, Bd Max Instrument |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.46 | 2022-2023 | Trulance |
| Avion Pharmaceuticals | $32.23 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $30.34 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $30.08 | 2022 | |
| Lilly USA, LLC | $30.05 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $27.06 | 2025 | |
| Abbott Laboratories | $23.98 | 2021 | |
| Agile Therapeutics, INC. | $22.40 | 2022 | |
| Millicent US INC | $22.14 | 2025 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $21.13 | 2025 | Gardasil 9 |
| Vertex Pharmaceuticals Incorporated | $19.64 | 2025 | |
| Pfizer INC. | $17.21 | 2023 | |
| Medtronic, INC. | $14.94 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.87 | 2020 | |
| Urovant Sciences INC | $13.84 | 2022 | |
| Dysis Medical, INC. | $13.31 | 2021 | |
| Allergan, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Vierling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.